Related Experiment Video
Updated: Apr 7, 2026
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease
Seyyedeh Saneeymehri1, Katherine Baker2, Tsz-Yin So1
1Department of Pharmacy, Moses H. Cone Hospital, Greensboro, North Carolina.
Insights
Kawasaki disease, an autoimmune condition in young children, involves inflammation of blood vessels. While often treatable, some cases are refractory, necessitating further research for effective management strategies.
Area of Science:
- Pediatrics
- Immunology
- Rheumatology
Background:
- Kawasaki disease is a primary autoimmune illness affecting children under 5, with higher incidence in Asian populations.
- It presents as acute vasculitis impacting skin, eyes, lymph nodes, and mucous membranes.
- While typically self-limiting, cardiac complications can be fatal.
Purpose of the Study:
- To review the current understanding of Kawasaki disease, focusing on its characteristics, causes, and treatment.
- To highlight the challenges in managing refractory cases due to limited clinical trials.
Main Methods:
- Review of existing literature on Kawasaki disease.
- Analysis of treatment outcomes from observational studies and case reports.
Main Results:
- Initial treatment with intravenous immune globulin and aspirin is effective for most patients.
- Up to 25% of patients exhibit refractoriness to initial therapy, requiring alternative treatments.
- Lack of randomized controlled trials complicates treatment decisions for refractory Kawasaki disease.
Conclusions:
- Current treatment guidelines for refractory Kawasaki disease rely on limited data from observational studies and case reports.
- Further large-scale, randomized controlled trials are essential to establish definitive treatment protocols for refractory cases.
- Clinical expertise remains crucial in managing refractory Kawasaki disease in the absence of robust trial data.
Abstract:
Kawasaki disease is an autoimmune disease found predominantly in children under the age of 5 years. Its incidence is higher in those who live in Asian countries or are of Asian descent. Kawasaki disease is characterized as an acute inflammation of the vasculature bed affecting mainly the skin, eyes, lymph nodes, and mucosal layers. Although the disease is usually self-limiting, patients may develop cardiac abnormalities that can lead to death. The exact cause of the disease is unknown; however, researchers hypothesize that an infectious agent is responsible for causing Kawasaki disease. Initial treatment options with intravenous immune globulin and aspirin are sufficient to cure most patients who acquire this disease. Unfortunately, in up to one-quarter of patients, the disease will be refractory to initial therapy and will require further management with corticosteroid, immunomodulatory, or cytotoxic agents. The lack of randomized, controlled trials makes treatment of refractory disease difficult to manage. Until larger randomized, controlled trials are published to give more guidance on therapy for this stage of disease, clinicians should use the data available from observational studies and case reports in conjunction with their clinical expertise to make treatment decisions.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:21Rheumatic Heart Disease III: Medical Management
01:26Mitral Stenosis III: Medical Management
01:14Myocarditis III: Medical Management
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System